Ultragenyx is trading 5.8% up at $15.49 as investors continue repricing the company following the September 17, 2026 FDA approval of FAYUVI, the first approved treatment for Sanfilippo syndrome type A.
- Reuters reported a $3.95 million list price.
- Cantor Fitzgerald and Citi raised their price targets, reinforcing optimism about the commercial opportunity.
- Major indexes are mixed; shares are extending the September 17 rally. No current volume figure was provided.